Recent developments at the Food and Drug Administration have centered on the resignation of Commissioner Marty Makary in mid-May 2026, followed by President Trump’s Truth Social announcement naming Kyle Diamantas acting commissioner. This direct endorsement from the administration has elevated Diamantas in trader assessments for a formal permanent selection, reflecting the White House’s preference for continuity within the agency’s leadership structure. Senate confirmation remains a required step under standard executive branch procedures, and the market’s December 31 resolution window leaves room for additional candidates or delays. Other listed individuals show limited recent signals of consideration, underscoring how the acting appointment and timing of the leadership transition continue to shape implied probabilities among participants.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · ZaktualizowanoKyle Diamantas 57%
No announcement by December 31 12.3%
Stephen Hahn 5%
Brett Giroir 3.5%
NOWE
NOWE
Dec 31, 2026
Kyle Diamantas
57%
Stephen Hahn
5%
Brett Giroir
3%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
12%
Kyle Diamantas 57%
No announcement by December 31 12.3%
Stephen Hahn 5%
Brett Giroir 3.5%
NOWE
NOWE
Dec 31, 2026
Kyle Diamantas
$1,525 Wol.
57%
Stephen Hahn
$976 Wol.
5%
Brett Giroir
$1,510 Wol.
3%
Grace Graham
$1,893 Wol.
3%
Sara Brenner
$849 Wol.
3%
No announcement by December 31
$533 Wol.
12%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent developments at the Food and Drug Administration have centered on the resignation of Commissioner Marty Makary in mid-May 2026, followed by President Trump’s Truth Social announcement naming Kyle Diamantas acting commissioner. This direct endorsement from the administration has elevated Diamantas in trader assessments for a formal permanent selection, reflecting the White House’s preference for continuity within the agency’s leadership structure. Senate confirmation remains a required step under standard executive branch procedures, and the market’s December 31 resolution window leaves room for additional candidates or delays. Other listed individuals show limited recent signals of consideration, underscoring how the acting appointment and timing of the leadership transition continue to shape implied probabilities among participants.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Rynek otwarty: May 12, 2026, 7:59 PM ET
Wolumen
$7,286Data zakończenia
Dec 31, 2026Rynek otwarty
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent developments at the Food and Drug Administration have centered on the resignation of Commissioner Marty Makary in mid-May 2026, followed by President Trump’s Truth Social announcement naming Kyle Diamantas acting commissioner. This direct endorsement from the administration has elevated Diamantas in trader assessments for a formal permanent selection, reflecting the White House’s preference for continuity within the agency’s leadership structure. Senate confirmation remains a required step under standard executive branch procedures, and the market’s December 31 resolution window leaves room for additional candidates or delays. Other listed individuals show limited recent signals of consideration, underscoring how the acting appointment and timing of the leadership transition continue to shape implied probabilities among participants.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Wolumen
$7,286Data zakończenia
Dec 31, 2026Rynek otwarty
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...Recent developments at the Food and Drug Administration have centered on the resignation of Commissioner Marty Makary in mid-May 2026, followed by President Trump’s Truth Social announcement naming Kyle Diamantas acting commissioner. This direct endorsement from the administration has elevated Diamantas in trader assessments for a formal permanent selection, reflecting the White House’s preference for continuity within the agency’s leadership structure. Senate confirmation remains a required step under standard executive branch procedures, and the market’s December 31 resolution window leaves room for additional candidates or delays. Other listed individuals show limited recent signals of consideration, underscoring how the acting appointment and timing of the leadership transition continue to shape implied probabilities among participants.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania